KPMG Australia Appoints John Sams as CEO Following Audit Leak Scandal 
Asian Stocks Rally on AI Spending Optimism as Middle East Tensions Push Oil to Six-Week High 
Super Micro Computer Stock Jumps 20% After Record AI Orders and Margin Surge 
Volkswagen Cuts 2026 Revenue Outlook as China Weakness, Trade Risks Weigh 
Nike Shifts China Online Sales Strategy to Boost Brand and Fight Local Rivals 
Gold Price Surges Above $4,100 as Middle East Tensions Boost Safe-Haven Demand 
Nasdaq Drops as AI Earnings, Oil Surge and Middle East Tensions Weigh on Wall Street 
Trump Threatens Iran With 'Major Military Punishment' as Red Sea Attacks Push Oil Above $100 
Scandinavian Tobacco Group Sells BREAK and Moro Brands to Japan Tobacco for €176 Million 
IBM Q2 Earnings Miss Estimates as Software Growth Offsets Infrastructure Weakness 
Wistron Opens $700M Texas AI Factory to Build Nvidia GB300 Superchips 
Oil Prices Head for Weekly Surge as Red Sea Attacks and Kazakhstan Supply Cuts Raise Disruption Fears 
GM Q2 Earnings Beat Estimates as General Motors Raises 2026 Profit Outlook 
OpenAI Australia Data Center Switches Cooling Strategy After Recycled Water Plan Fails 
Alphabet Q2 Earnings Beat Estimates as AI Spending, Google Cloud Growth Fuel Outlook 
Elon Musk Fuels SpaceX-Tesla Merger Speculation After Earnings Call 
LG Chem Ltd. announced it set to buy AVEO Pharmaceuticals for $566 million or $15 per share in full cash. The South Korean chemical company headquartered in Seoul is aiming to purchase a 100% stake in the Boston-based company.
With the acquisition, LG Chem will expand its commercial footprint in the US market for a wide range of oncology therapies. The company also revealed on Tuesday, Oct. 18, that it will also use the deal to branch out to other related fields.
According to The Korea Times, AVEO Pharma developed FOTIVDA prescription medicine made for the treatment of relapsed or refractory advanced renal cell carcinoma (RCC). this drug was only approved in March 2021 by the U.S. Food and Drug Administration (FDA).
LG Chem said that this is the first time that a South Korean company is buying a firm that has been granted approval by the FDA for a new type of drug. As it acquires AVEO, the company is planning to invest in LG Chem Life Science Innovation Center so it can establish a special purpose company for the takeover of the US-based pharma firm.
Moreover, the deal will provide LG Chem’s Life Sciences unit with a commercial presence in the United States. This will also speed up the company’s efforts to deliver its continued growth.
The transaction is expected to close in early 2023, and as with any other buyout deals, this is still subject to customary closing conditions. It should be approved by AVEO’s shareholders and go through regulatory processes.
“With its track record of clinical success, deep pipeline of innovative therapies and continued growth trajectory following the successful commercialization of FOTIVDA, AVEO is the perfect partner for LG Chem Life Sciences,” LG Chem’s chief executive officer, Shin Hak Cheol, said in a press release. “This transaction represents the next step in our portfolio transformation towards higher growth markets and provides a strong commercial foundation in oncology as we continue to develop our anti-cancer offerings.
The CEO further said, “We remain focused on prudently investing in our R&D capabilities, continuing to build a leading portfolio of therapies and transforming lives through inspiring science and leading innovation.”
